Leukemia xenograft regression and survival after treatment with anti-CD45 PRIT using 90Y-DOTA-biotin. Athymic mice bearing HEL xenografts were injected intravenously via tail vein 2 days after tumor implantation with 1.4 nmol of anti-CD45 Ab-SA conjugate followed 22 hours later with 5.8 nmol of CA and then with 1.2 nmol of 90Y-DOTA-biotin (800 μCi and 1200 μCi) 3 hours later. Tumor-bearing control mice were either untreated or treated with a nonbinding control Ab-SA conjugate before 1200 μCi radiolabeled DOTA-biotin injection. (A) Tumor volume curves are truncated at the time of death because of excessive tumor growth in the first mouse in each group. (B) Mice were analyzed for survival as a function of time. †Deaths resulting from toxicity.
